• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

分析四个国家七种不同的 SARS-CoV-2 疫苗的免疫时间、幅度和不良反应。

Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries.

机构信息

Research Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo Leon, Mexico.

Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García, Mexico.

出版信息

Front Immunol. 2022 Jul 28;13:894277. doi: 10.3389/fimmu.2022.894277. eCollection 2022.

DOI:10.3389/fimmu.2022.894277
PMID:35967368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9367469/
Abstract

BACKGROUND

Scarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-CoV-2 vaccines. Our aim was to correlate the magnitude of the antibody response to vaccination with previous clinical conditions and AEFI.

METHODS

A multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers were measured at baseline, 21-28 days after the first and second dose (when applicable) of the following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV and Ad26.COV2. Mixed model and Poisson generalized linear models were performed.

RESULTS

We recruited 1867 individuals [52 (SD 16.8) years old, 52% men]. All vaccines enhanced anti-S1 and anti-S2 IgG antibodies over time (p<0.01). The highest increase after the first and second dose was observed in mRNA-1273 (p<0.001). There was an effect of previous SARS-CoV-2 infection; and an interaction of age with previous SARS-CoV-2 infection, Gam-COVID-Vac and ChAdOx1-S (p<0.01). There was a negative correlation of Severe or Systemic AEFI (AEs) of naïve SARS-CoV-2 subjects with age and sex (p<0.001); a positive interaction between the delta of antibodies with Gam-COVID-Vac (p=0.002). Coronavac, Gam-COVID-Vac and ChAdOx1-S had less AEs compared to BNT162b (p<0.01). mRNA-1273 had the highest number of AEFIs. The delta of the antibodies showed an association with AEFIs in previously infected individuals (p<0.001).

CONCLUSIONS

The magnitude of seroconversion is predicted by age, vaccine type and SARS-CoV-2 exposure. AEs are correlated with age, sex, and vaccine type. The delta of the antibody response only correlates with AEs in patients previously exposed to SARS-CoV-2.

REGISTRATION NUMBER

ClinicalTrials.gov, identifier NCT05228912.

摘要

背景

关于不同 SARS-CoV-2 疫苗接种后的血清转化率和不良事件（AEFI）比较，相关信息十分匮乏。我们的目的是将疫苗接种后的抗体反应程度与既往临床情况和 AEFI 相关联。

方法

这是一项多中心的对比研究，在以下疫苗接种后第 21-28 天（适用时）以及基线时，测量 SARS-CoV-2 刺突 1-2 IgG 抗体 IgG 滴度：BNT162b2 mRNA、mRNA-1273、Gam-COVID-Vac、Coronavac、ChAdOx1-S、Ad5-nCoV 和 Ad26.COV2。采用混合模型和泊松广义线性模型进行分析。

结果

我们共招募了 1867 名个体[52（SD 16.8）岁，52%为男性]。所有疫苗均能随时间提高抗 S1 和抗 S2 IgG 抗体（p<0.01）。mRNA-1273 在第一和第二剂后观察到的增幅最大（p<0.001）。既往 SARS-CoV-2 感染存在影响；年龄与既往 SARS-CoV-2 感染、Gam-COVID-Vac 和 ChAdOx1-S 之间存在交互作用（p<0.01）。无 SARS-CoV-2 既往感染的严重或全身性 AEFI（AE）与年龄和性别呈负相关（p<0.001）；Gam-COVID-Vac 的抗体差值与 AE 呈正交互作用（p=0.002）。与 BNT162b 相比，Coronavac、Gam-COVID-Vac 和 ChAdOx1-S 的 AE 更少（p<0.01）。mRNA-1273 的 AEFIs 数量最多。既往感染个体的抗体差值与 AEFIs 相关（p<0.001）。

结论

血清转化率的大小由年龄、疫苗类型和 SARS-CoV-2 暴露情况预测。AE 与年龄、性别和疫苗类型相关。抗体反应的差值仅与既往 SARS-CoV-2 暴露的患者的 AE 相关。

注册号

ClinicalTrials.gov，标识符 NCT05228912。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df9/9367469/4e2bf21991a9/fimmu-13-894277-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df9/9367469/6861c750c787/fimmu-13-894277-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df9/9367469/48b4af384fb3/fimmu-13-894277-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df9/9367469/d2d340fe58c6/fimmu-13-894277-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df9/9367469/4e2bf21991a9/fimmu-13-894277-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df9/9367469/6861c750c787/fimmu-13-894277-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df9/9367469/48b4af384fb3/fimmu-13-894277-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df9/9367469/d2d340fe58c6/fimmu-13-894277-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df9/9367469/4e2bf21991a9/fimmu-13-894277-g004.jpg

相似文献

1
Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries.分析四个国家七种不同的 SARS-CoV-2 疫苗的免疫时间、幅度和不良反应。
Front Immunol. 2022 Jul 28;13:894277. doi: 10.3389/fimmu.2022.894277. eCollection 2022.
2
COVID-19 Vaccines2019冠状病毒病疫苗
3
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
4
Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.在有和没有先前 SARS-CoV-2 感染的人群中，COVID-19 mRNA 疫苗加强针接种后和 COVID-19 后心肌炎和心包炎的风险：在英国的一项自身对照病例系列分析。
PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. eCollection 2023 Jun.
5
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
6
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
7
The impact of vaccine booster doses on specific B- and T-lymphocyte dynamics in Thai healthcare personnel following COVID-19 vaccination.新冠疫苗接种后，加强针剂量对泰国医护人员特定B淋巴细胞和T淋巴细胞动态变化的影响
Sci Rep. 2025 Jul 16;15(1):25713. doi: 10.1038/s41598-025-10400-8.
8
Establishment of human post-vaccination SARS-CoV-2 standard reference sera.建立人接种 SARS-CoV-2 疫苗后标准参考血清。
J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.
9
Immunogenicity and safety study of a single dose of SpikoGen® vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.单剂量SpikoGen®疫苗作为异源或同源肌肉注射加强针，在门诊成人中于mRNA、腺病毒载体或重组蛋白COVID-19疫苗初免后进行的免疫原性和安全性研究。
Vaccine. 2025 Mar 7;49:126744. doi: 10.1016/j.vaccine.2025.126744. Epub 2025 Feb 5.
10
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

引用本文的文献

1
Prevalence of Adverse Events Reported Following the First Dose of COVID-19 Vaccines in Bahia State, Brazil, from 2021 to 2022.2021年至2022年巴西巴伊亚州首剂新冠疫苗接种后报告的不良事件发生率
Vaccines (Basel). 2025 Feb 7;13(2):161. doi: 10.3390/vaccines13020161.
2
The Relationship between Immunogenicity and Reactogenicity of Seasonal Influenza Vaccine Using Different Delivery Methods.使用不同递送方法的季节性流感疫苗的免疫原性与反应原性之间的关系
Vaccines (Basel). 2024 Jul 21;12(7):809. doi: 10.3390/vaccines12070809.
3
Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina.

本文引用的文献

1
Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review.COVID-19 疫苗在健康成年人中的免疫原性和安全性与对照相比：定性和系统评价。
Value Health. 2022 May;25(5):717-730. doi: 10.1016/j.jval.2021.09.003. Epub 2021 Oct 15.
2
The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients.有症状的患者对新冠病毒感染的抗体反应至少持续8个月。
Commun Med (Lond). 2021;1(1):32. doi: 10.1038/s43856-021-00032-0. Epub 2021 Sep 17.
3
Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines.
墨西哥和阿根廷六个月随访期间不同加强疫苗组合对 SARS-CoV-2 的有效性。
Front Immunol. 2024 May 14;15:1403784. doi: 10.3389/fimmu.2024.1403784. eCollection 2024.
4
Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study.卡塔尔基层医疗环境中BNT162b2疫苗的短期副作用：一项回顾性研究。
Front Public Health. 2024 Apr 10;12:1384327. doi: 10.3389/fpubh.2024.1384327. eCollection 2024.
5
Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia.印度尼西亚医护人员接种mRNA疫苗作为异源新冠病毒疫苗加强针后的抗体反应及不良反应评估
Vaccines (Basel). 2023 Jun 26;11(7):1160. doi: 10.3390/vaccines11071160.
6
A study of the efficacy and safety of plaque psoriasis treatment by TNF-α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine.一项研究 TNF-α 和 IL-17A 抑制剂生物制剂治疗斑块状银屑病的疗效和安全性，这些患者接受了已灭活的 SARS-CoV-2 疫苗。
Immun Inflamm Dis. 2023 Jul;11(7):e938. doi: 10.1002/iid3.938.
7
Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination.疫苗平台和卡介苗接种对 COVID-19 疫苗接种抗体反应的影响。
Front Immunol. 2023 Jul 3;14:1172851. doi: 10.3389/fimmu.2023.1172851. eCollection 2023.
8
Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico.六种不同的新冠病毒疫苗在巴西和墨西哥六个月随访及五次新冠疫情浪潮期间的有效性
Vaccines (Basel). 2023 Apr 14;11(4):842. doi: 10.3390/vaccines11040842.
9
Antibody response to different COVID-19 vaccines among the migrant workers of Bangladesh.孟加拉国农民工对不同 COVID-19 疫苗的抗体反应。
Front Immunol. 2023 Mar 9;14:1128330. doi: 10.3389/fimmu.2023.1128330. eCollection 2023.
10
COVID-19 vaccines and a perspective on Africa.COVID-19 疫苗和非洲视角。
Trends Immunol. 2023 Mar;44(3):172-187. doi: 10.1016/j.it.2023.01.005. Epub 2023 Jan 11.
针对刺突蛋白的抗新型严重急性呼吸综合征冠状病毒2免疫球蛋白G：BNT162b2、mRNA-1273、ChAdOx1新型冠状病毒疫苗2019和Ad26.COV2.S疫苗的比较
Vaccines (Basel). 2022 Jan 10;10(1):99. doi: 10.3390/vaccines10010099.
4
Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19.辉瑞/生物科技 BNT162b2：澳大利亚大规模 COVID-19 疫苗接种诊所的不良事件和见解。
Intern Med J. 2022 Jan;52(1):121-124. doi: 10.1111/imj.15623.
5
Humoral immune response after different SARS-CoV-2 vaccination regimens.不同 SARS-CoV-2 疫苗接种方案后的体液免疫应答。
BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x.
6
Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗与接种：老年人群的考量因素
Vaccines (Basel). 2021 Dec 4;9(12):1435. doi: 10.3390/vaccines9121435.
7
Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine.接种BNT162b2或ChAdOx1新冠疫苗的医护人员血清抗体反应比较及不良反应分析
Vaccines (Basel). 2021 Nov 24;9(12):1379. doi: 10.3390/vaccines9121379.
8
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.一项国际、多中心、随机、双盲、安慰剂对照的 III 期临床试验中，重组新型冠状病毒疫苗（腺病毒 5 型载体）在 18 岁及以上成年人中的单次剂量的最终疗效分析、中期安全性分析和免疫原性。
Lancet. 2022 Jan 15;399(10321):237-248. doi: 10.1016/S0140-6736(21)02753-7. Epub 2021 Dec 23.
9
Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.分析接种 COVID-19 疫苗的类型和不良反应。
JAMA Netw Open. 2021 Dec 1;4(12):e2140364. doi: 10.1001/jamanetworkopen.2021.40364.
10
Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals.在有 SARS-CoV-2 感染史的个体中，单次接种 BNT162b2 mRNA 疫苗后可观察到强大的免疫反应。
Sci Transl Med. 2022 Feb 9;14(631):eabi8961. doi: 10.1126/scitranslmed.abi8961.